🏛️ Verified NIH Record • Updated 2026-06-15
Hypofractionated LocoRegional Radiotherapy in Breast Cancer (NCT04228991)
Randomized Trial of Hypofractionated LocoRegional Radiotherapy in Breast Cancer and Lymphedema (RHEAL)
🔵 Active, Not Recruiting Phase3 📋 Clinical Research Protocol Sponsor: Ontario Clinical Oncology Group (OCOG)
🩺 Plain-English Summary (8th-Grade Level)
The primary objective of this study is to determine if hypofractionated RT delivered over 1 week to the breast or chest wall and regional nodes (26Gy in 5 daily fractions) following BCS or mastectomy, is non-inferior to conventional fractionation to the breast or chest wall and regional nodes delivered over 3 weeks (40Gy in 15 daily fractions) in patients with node-positive breast cancer.
Who can join: Review the eligibility criteria below.
Location: Tom Baker Cancer Centre — Calgary, Alberta
Age range: 18 Years
🧪 Interventions in This Study
- Locoregional radiation treatment - Conventional fractionation (RADIATION)
- Locoregional radiation treatment - Hypofractionation (RADIATION)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (20 Sites)
- Tom Baker Cancer Centre — Calgary, Alberta
- Cross Cancer Institute — Edmonton, Alberta
- BC Cancer - Centre for the Southern Interior — Kelowna, British Columbia
- BC Cancer - Centre for the North — Prince George, British Columbia
- BC Cancer - Vancouver Centre — Vancouver, British Columbia
- BC Cancer - Vancouver Island Centre — Victoria, British Columbia
- Northeast Cancer Centre, Health Sciences North — Greater Sudbury, Ontario
- Juravinski Cancer Centre — Hamilton, Ontario
- London Regional Cancer Program — London, Ontario
- The Ottawa Hospital Regional Cancer Centre — Ottawa, Ontario
- Sunnybrook Health Sciences Centre - Odette Cancer Centre — Toronto, Ontario
- Princess Margaret Cancer Centre - UHN — Toronto, Ontario
- Hotel-Dieu de Lévis (CISSS CA) — Lévis, Quebec
- CIUSSS de l'Est-de-l'Île de Montréal, Hôpital, Maisonneuve-Rosemont — Montreal, Quebec
- McGill University Health Centre-Cedars Cancer Centre — Montreal, Quebec
- CHUM - Centre Hospitalier de L'Universite de Montreal — Montreal, Quebec
- CHU-de Québec-Université de Laval — Québec, Quebec
- Sherbrooke University Hospital Centre — Sherbrooke, Quebec
- Allan Blair Cancer Centre — Regina, Saskatchewan
- Saskatoon Cancer Centre — Saskatoon, Saskatchewan
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Neoplasms
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) — Birmingham, Alabama
- (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer — Phoenix, Arizona
- Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer — Dallas, Texas
- Assessment of Quality of Life and Treatment Times for Patients With Invasive Type Breast Cancer in Martinique — Fort-de-France,
- Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer — Springdale, Arkansas
- The IDEA Study (Individualized Decisions for Endocrine Therapy Alone) — Stanford, California
Explore by condition: All Breast Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.